ILMN
$76.35
Illumina
$1.82
2.44%
ILMN
Earnings Whisper ®
N/A
1st Quarter March 2025
Consensus:  $0.96
Revenue:  $1.04 Bil
Thursday
May 8
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ILMN reports earnings?
Beat
Meet
Miss

Where is ILMN's stock price going from here?
Up
Flat
Down
Stock chart of ILMN
Analysts
Summary of analysts' recommendations for ILMN
Score
Grade
Pivots
Resistance
$80.10
$78.36
$77.35

$75.61

Support
$74.60
$72.86
$71.85
Tweet
Growth
Description
Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
Peers
CoherentAgilent TechnologiesBio-Rad LaboratoriesHarvard Bioscience